---
layout: post
title: "Potency Assurance for Cellular and Gene Therapy Products; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:58:08 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-28596
original_published: 2023-12-28 00:00:00 +0000
significance: 8.00
---

# Potency Assurance for Cellular and Gene Therapy Products; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:58 UTC
**Source:** Federal Register
**Original Published:** December 28, 2023 00:00 UTC
**Document Number:** 2023-28596

## Summary

The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance entitled "Potency Assurance for Cellular and Gene Therapy Products." FDA is issuing this draft guidance to provide recommendations to help assure the potency of human cellular therapy or gene therapy (CGT) products at all stages of the product lifecycle. FDA is recommending a comprehensive approach to potency assurance of CGT products that is grounded in quality risk management. For investigational products, we describe how to progressively implement a strategy for potency assurance during product development and provide additional considerations to help assure the potency of products that are undergoing rapid clinical development. For licensed products, we describe requirements for potency assurance, including testing required for lot release.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/12/28/2023-28596/potency-assurance-for-cellular-and-gene-therapy-products-draft-guidance-for-industry-availability)
- API: https://www.federalregister.gov/api/v1/documents/2023-28596

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
